BNP Paribas Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

BNP Paribas Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-72,106	Closed	-$15.4M	–	2262
2025 Q4	$15.4M	Sell	72,106 -117,548	-62%	-$24.3M	0.02%	581
2025 Q3	$37.7M	Sell	189,654 -87,330	-32%	-$16.3M	0.1%	224
2025 Q2	$47.8M	Sell	276,984 -53,169	-16%	-$8.66M	0.12%	181
2025 Q1	$51.5M	Buy	330,153 +13,573	+4%	+$1.94M	0.14%	153
2024 Q4	$43.6M	Buy	316,580 +72,724	+30%	+$9.56M	0.11%	199
2024 Q3	$36.4M	Buy	243,856 +80,746	+50%	+$10.9M	0.09%	226
2024 Q2	$22.2M	Buy	163,110 +76,908	+89%	+$10.5M	0.06%	274
2024 Q1	$13M	Buy	+86,202	New	+$12.3M	0.03%	386
2022 Q3	–	Sell	-6,729	Closed	-$626K	–	903
2022 Q2	$626K	Buy	+6,729	New	+$634K	﹤0.01%	829

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BNP Paribas Asset Management's ASND Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 72,106 shares — an estimated $15.4M sold.

BNP Paribas Asset Management first reported a position in ASND in Q2 2022 and held it in 9 quarters. The position peaked at $51.5M in Q1 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

BNP Paribas Asset Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
BNP Paribas Asset Management sold 72,106 Ascendis Pharma A/S shares in Q1 2026, an estimated $15.4M.
BNP Paribas Asset Management first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 9 quarters.
BNP Paribas Asset Management's Ascendis Pharma A/S position peaked at $51.5M in Q1 2025.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.